Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Increase in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 16,753 shares, an increase of 26.7% from the January 15th total of 13,222 shares. Based on an average trading volume of 57,316 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the company’s stock are sold short. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 57,316 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Several analysts have recently commented on CMMB shares. Zacks Research downgraded shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Chemomab Therapeutics in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $26.50.

Institutional Investors Weigh In On Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC acquired a new stake in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 51,710 shares of the company’s stock, valued at approximately $85,000. Kestra Private Wealth Services LLC owned about 0.84% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Chemomab Therapeutics Stock Performance

Shares of NASDAQ:CMMB opened at $1.51 on Tuesday. The company has a market capitalization of $9.30 million, a P/E ratio of -0.51 and a beta of 0.56. The company’s 50-day moving average is $1.78 and its 200 day moving average is $2.60. Chemomab Therapeutics has a fifty-two week low of $1.42 and a fifty-two week high of $8.24.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.